Reaction equation
[NH2:1][CH:2]([C:5]1[C:6](=[O:16])[NH:7][C:8]([CH:11]2[CH2:15][CH2:14][CH2:13][CH2:12]2)=[N:9][N:10]=1)[CH2:3][CH3:4].[CH2:17]([O:24][C:25]([N:27]1[CH2:32][CH2:31][CH:30]([C:33](O)=[O:34])[CH2:29][CH2:28]1)=[O:26])[C:18]1[CH:23]=[CH:22][CH:21]=[CH:20][CH:19]=1>>[CH:11]1([C:8]2[NH:7][C:6](=[O:16])[C:5]([CH:2]([NH:1][C:33]([CH:30]3[CH2:31][CH2:32][N:27]([C:25]([O:24][CH2:17][C:18]4[CH:19]=[CH:20][CH:21]=[CH:22][CH:23]=4)=[O:26])[CH2:28][CH2:29]3)=[O:34])[CH2:3][CH3:4])=[N:10][N:9]=2)[CH2:15][CH2:14][CH2:13][CH2:12]1Participants
3
Procedure
In analogy to the procedure for Example 58A, 300 mg (1.35 mmol) 6-(1-aminopropyl)-3-cyclopentyl-1,2,4-triazin-5(4H)-one, 355 mg (1.35 mmol) 1-[(benzyloxy)carbonyl]-4-piperidinecarboxylic acid and proportionate amounts of the other reagents are used. The crude product is used in the next step without further purification.
Workup
- customThe crude product is used in the next step without further purification
Sources & evidence
- ORD record
- ord-c64acda377b04231a8bd09f8e64f3cb5
- Source dataset
- uspto-grants-2006_08
- Patent number
- US07087605B2
Linked notes
Loading…